Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 6Prostatic Neoplasms 2Lymphoma, Follicular 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Locally Advanced Esophageal or GE Junction Cancer 1Hormone Refractory Prostate Cancer 1Disease 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Rituximab 43Cyclophosphamide 26fludarabine 15ibrutinib 14Vincristine 11Prednisone 11Doxorubicin 11pirtobrutinib 10Bendamustine Hydrochloride 10obinutuzumab 9polatuzumab vedotin 6Inotuzumab Ozogamicin 6tocilizumab 5pembrolizumab 5glofitamab 5Gemcitabine 5zanubrutinib 4venetoclax 4ublituximab 4Lenalidomide 4Brentuximab Vedotin 4Antigens, CD19 4tazemetostat 3acalabrutinib 3Everolimus 3DTRMWXHS-12 3veltuzumab 2sepantronium 2iberdomide 2denileukin diftitox 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, B-Cell × gossypol acetic acid × Clear all
NCT05338931 2022-05-26

Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

AbClon

Phase 1/2 Recruiting
82 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡